Johnson & Johnson (J&J) ends late-stage HIV vaccine trial; mothers in states with abortion bans are almost 3 times more likely to die before, during, and after birth; Sanofi hopes to release a drug for hemophilia A in 2023.
J&J Will Stop HIV Vaccine Trial
Following evidence of ineffectiveness against infection prevention, Johnson & Johnson (J&J) will discontinue a late-stage worldwide trial of an HIV vaccine, Reuters reported. The news comes over a year after another unsuccessful vaccine study by J&J. A spokesperson who was a partner in the trial said that they will take the information from this trial put it to use in the future. The study started in 2019 at more than 50 locations, comprising about 3900 gay men and transgender people, who are deemed most susceptible to the infection.
States Banning Abortion More Likely to Have Maternal Deaths
Death in women during pregnancy, childbirth, or postpartum is almost 3 times more likely in states with abortion bans, Axios said, after reviewing a report from the Gender Equity Policy Institute. Almost 60% of US women live in states that ban or restrict abortion and other reproductive health care. In 2021, the maternal mortality rate in states with abortion bans was 2.4 times higher than that of states supporting abortion, according to the report, with women of color being the most affected.
Sanofi Strives to Introduce Hemophilia A Drug in 2023
French drug manufacturer Sanofi SA has high hopes for efanesoctocog alfa, its hemophilia A drug, in 2023, according to Reuters. The drug is being created in conjunction with Swedish drug producer Sobi; a decision by the FDA is expected by February 28. The marketing application was accepted by the FDA in 2022. An estimated 400 babies per year are born with the disorder, and possibly more.
Atypical Marker Expression in T-Cell Acute Lymphoblastic Leukemia/Lymphoma
May 15th 2024Two unique case reports highlight the diagnostic challenges and critical importance of comprehensive immunophenotyping in cases of T-cell acute lymphoblastic leukemia/lymphoma that present without typical immaturity markers but with rare γδ T-cell receptor expression.
Read More
Panel Addresses Minority Physician Shortage, Maternal Health, at Senate Committee Hearing
May 15th 2024The senate hearing held by the US Senate Committee on Health, Education, Labor, and Pensions, led by Sen. Bernie Sanders (I, Vermont), chairman of the committee, and ranking member Sen. Bill Cassidy, MD, (R, Louisiana), addressed the critical issue of physician and health care worker shortages, as well as the maternal health crisis, in the US.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Patients With MG Report Higher Azathioprine Discontinuation vs Other Immunosuppressants
May 15th 2024Survey data from over 200 patients showed that treatment discontinuation was lower for those taking mycophenolate or methotrexate than for those taking azathioprine for their myasthenia gravis (MG).
Read More
Bleeds and Resource Use in Hemophilia B: Retrospective Observational Study
May 15th 2024This real-world US study describes individuals with hemophilia B who experience bleeds despite factor replacement therapy and quantifies the associated comorbidity and health care resource utilization burden.
Read More